TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03331757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citrus honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of citrus honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pine honey
Description: Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of pine honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study: NCT03823690

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided gastrojejunstomy
Description: As listed in the arms description

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The pyloro-duodenal stent
Description: As listed in the arms description
Study: NCT03999203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid
Description: Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid
Description: Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid
Description: Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leicester Cough monitor
Description: Ambulatory cough monitor to assess cough frequency over a 24 hour period

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leicester Cough monitor
Description: Ambulatory cough monitor to assess cough frequency over a 24 hour period

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leicester Cough monitor
Description: Ambulatory cough monitor to assess cough frequency over a 24 hour period
Study: NCT01106456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)
Study: NCT03999203

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leicester Cough monitor
Description: Ambulatory cough monitor to assess cough frequency over a 24 hour period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fractional exhaled nitric oxide testing (FeNO)
Description: Measurement of exhaled nitric oxide to give an indication of airway inflammation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fractional exhaled nitric oxide testing (FeNO)
Description: Measurement of exhaled nitric oxide to give an indication of airway inflammation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fractional exhaled nitric oxide testing (FeNO)
Description: Measurement of exhaled nitric oxide to give an indication of airway inflammation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fractional exhaled nitric oxide testing (FeNO)
Description: Measurement of exhaled nitric oxide to give an indication of airway inflammation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient reported outcome measures
Description: A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient reported outcome measures
Description: A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
Study: NCT01224249

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish and shellfish
Description: Intake of 1000 grams of fish and shellfish per week for six months.
Study: NCT03999203

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient reported outcome measures
Description: A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient reported outcome measures
Description: A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
Study: NCT03813316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor
Description: Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).
Study: NCT02464215

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: Subtotal gastectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dessection(around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. Dissected stomach and lymph node are collected through additional 5-10 cm incision at the preexisting epigastric incision.
Study: NCT00558441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVMRI
Description: Intra Vascular Magnetic Resonance Imaging
Study: NCT00268697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and ezetimibe
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
Study: NCT03813316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor
Description: Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Adding ertugliflozin (SGLT2i) add-on using a fixed-dose combination with metformin(Segluromet® 2.5/1000 mg BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Adding ertugliflozin (SGLT2i) add-on using a fixed-dose combination with metformin(Segluromet® 2.5/1000 mg BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor and DPP-4 inhibitor
Description: Adding both a DPP-4i as Fixed dose combination (Janumet) plus SGLT2i ertugliflozin (steglatro) as add-on to metformin.
Study: NCT04251325

Intervention type: OTHER
Intervention: Basic Life Support Courses
Description: 4 hours basic life support courses for laypersons
Study: NCT03067870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: * Intravenous administration of autologous bone marrow derived stem cells for immunomodulation.~* Transplantation of autologous bone marrow derived stem cells in joints.
Study: NCT02349815

Intervention type: DRUG
Intervention: Levonorgestrel (Jaydess, Skyla, BAY86-5028)
Description: Women use Levonorgestrel (Jaydess, BAY86-5028) .
Study: NCT04150900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).
Study: NCT03813316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor and DPP-4 inhibitor
Description: Adding both a DPP-4i as Fixed dose combination (Janumet) plus SGLT2i ertugliflozin (steglatro) as add-on to metformin.
Study: NCT04150900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study: NCT00599625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 80mg administered daily for 6 consecutive weeks
Study: NCT06092736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Danshen Dropping Pills
Description: Dosage of Compound Danshen Dropping Pills: 20 capsules each time, 3 times a day, after meals. The follow-up period was 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.
Study: NCT03665675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
Description: Given intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Description: Given intravenously
Study: NCT01595425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H Sachet 20 mg
Description: Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H HPMC capsule 20 mg
Description: Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.
Study: NCT01190436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
Study: NCT00119782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: A dietary intervention that will promote lower calorie intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: A dietary intervention that will promote lower calorie intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A physical activity intervention combining increased daily physical activity and regular, structured exercise
Study: NCT03661645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg IV dexamethasone & 6 day oral methylprednisolone taper
Description: Drug: 6-day oral methylprednisolone (glucocorticoid) taper course The oral methylprednisolone taper course will begin on the day of surgery and will include 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day.~Drug:10 mg intravenous (IV) dexamethasone

Intervention type: OTHER
Group type: OTHER
Intervention: 10 mg IV dexamethasone
Description: Drug:10 mg intravenous (IV) dexamethasone
Study: NCT01744639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HCC under treatment with radioablation
Description: The evaluation will take place over a period of 30 days.
Study: NCT03985540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavorial; memory exercise
Description: Memory training twice a week for 5 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; memory exercise
Description: Placebo Memory training twice a week for 5 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: speed exercises
Description: Speed training twice a week for 5 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo speed training
Description: Placebo Speed training twice a week for 5 weeks.
Study: NCT01077401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
Study: NCT04063163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and etoposide
Description: chemotherapeutics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin and etoposide
Description: chemotherapeutics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02781480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV RPE65
Description: Comparison of different dosages of AAV RPE65

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV RPE65
Description: Comparison of different dosages of AAV RPE65

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV RPE65
Description: Comparison of different dosages of AAV RPE65
Study: NCT03661333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavioral therapy
Description: DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly family meetings and individual therapy conducted in 60 minute biweekly sessions. Family skills training proceeds as follows: psychoeducation about DBT and bipolar disorder, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the adolescent in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants and their participating family members by cell phone for in-vivo skills coaching between sessions.
Study: NCT01848327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caprylic Triglyceride
Description: Caprylic Triglyceride is a medical food that is used for the dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (40 gram packet orally once a day for 90 days)
Study: NCT01483183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-108459
Description: Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target~Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-108459
Description: Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target~Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPC-108459
Description: Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target~Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose, 10-minute constant rate IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose, 10-minute constant rate IV infusion
Study: NCT03312842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001
Description: In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, patients will be assigned to different groups based on their tumor type.
Study: NCT04375059

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: using interactive attention training system
Description: using the interactive attention training system to children with Attention Deficit Hyperactivity Disorder
Study: NCT00932412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLARA
Description: Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDAc
Description: Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
Study: NCT01966835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity aerobic interval training
Description: The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
Study: NCT00466921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.
Study: NCT02742376

Intervention type: OTHER
Group type: OTHER
Intervention: Soft surface
Description: A sponge rectangle used in physiotherapy will be placed on the floor,

Intervention type: OTHER
Group type: OTHER
Intervention: Soft surface
Description: A sponge rectangle used in physiotherapy will be placed on the floor,

Intervention type: OTHER
Group type: OTHER
Intervention: Soft surface
Description: A sponge rectangle used in physiotherapy will be placed on the floor,

Intervention type: OTHER
Group type: OTHER
Intervention: Floor
Description: A marked path on the floor where the subject is instructed to walk.

Intervention type: OTHER
Group type: OTHER
Intervention: Floor
Description: A marked path on the floor where the subject is instructed to walk.

Intervention type: OTHER
Group type: OTHER
Intervention: Floor
Description: A marked path on the floor where the subject is instructed to walk.

Intervention type: OTHER
Group type: OTHER
Intervention: Kyboot shoes
Description: Special shoes will be worn by the subject.

Intervention type: OTHER
Group type: OTHER
Intervention: Kyboot shoes
Description: Special shoes will be worn by the subject.

Intervention type: OTHER
Group type: OTHER
Intervention: Kyboot shoes
Description: Special shoes will be worn by the subject.
Study: NCT00998088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: erythropoietin and cell saver
Description: weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: weekly 40.000 IU s.c. for 4 weeks pre-operatively

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPAT
Description: for intra- and post-operative re-infusion of autologous wound blood

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-operative drain device
Description: For post-operative re-infusion of unwashed wound blood

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythropoietin and OrthoPAT
Description: weekly 40.000 IU s.c. for 4 weeks pre-operatively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erythropoietin and drain device
Description: weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
Study: NCT00863265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00998088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPAT
Description: For intra- and post-operative reinfusion of autologous blood
Study: NCT01957371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Yoga Therapy
Description: Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, physical postures/movements, and guided rest (yoga nidra), as well as daily home practice.